The Association for Clinical Biochemistry & Laboratory Medicine

Summary of NICE Guidelines

Title	Golimumab for the treatment of methotrexate-naïve rheumatoid arthritis (terminated appraisal).
NICE Reference	TA224
Date of Review:	-
Date of Publication	June 2011
Summary of Guidance (Max 250 words)	• Golimumab is a TNF-α inhibitor used for the treatment of severe, active and progressive rheumatoid arthritis. • The manufacturer (Schering-Plough) decided not to submit evidence for this single technology appraisal (TA224) because current clinical practice and NICE guidance does not support the use of TNF inhibitors for patients *not* previously treated with methotrexate. Therefore the appraisal has been terminated. • This means NICE cannot recommend the use of golimumab for the treatment of methotrexate-naïve rheumatoid arthritis. NHS organizations who decide to do so, should take into consideration why the manufacturer did not make an evidence submission.
Impact on Lab (See below)	■ None
Lab professionals to be made aware	☐ Laboratory Manager ☐ Chemical Pathologist ☐ Clinical Scientist ☐ Biomedical Scientist
Please detail the impact of this guideline (Max 150 words)	None

Impact on Lab

■ **None**: This NICE guideline has no impact on the provision of laboratory services

■ **Moderate**: This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.

■ **Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Produced by Miss Krithika Subramaniam